Chris Hollis
Auto-generated profile, based on publicly available information

Chris Hollis

University of Nottingham, Nottingham, UK

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet Psychiatry
Verified
Journal Article
Open access
SCSamuele Cortese
Samuele Cortese
NANicoletta Adamo
Nicoletta Adamo
CGCinzia Del Giovane
Cinzia Del Giovane
CMChristina Mohr-Jensen
Christina Mohr-Jensen
AHAdrian J Hayes
Adrian J Hayes
ACAndrea Cipriani
Andrea Cipriani
The benefits and safety of medications for attention-deficit hyperactivity disorder (ADHD) remain controversial, and guidelines are inconsistent on which medications are preferred across different age groups. We aimed to estimate the comparative efficacy and tolerability of oral medications for ADHD in children, adolescents, and adults. We did a literature search for published and unpublished double-blind randomised controlled trials comparing amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with each other or placebo. We systematically contacted study authors and drug manufacturers for additional information. Primary outcomes were efficacy (change in severity of ADHD core symptoms based on teachers' and clinicians' ratings) and tolerability (proportion of patients who dropped out of studies because of side-effects) at timepoints closest to 12 weeks, 26 weeks, and 52 weeks. We estimated summary odds ratios (ORs) and standardised mean differences (SMDs) using pairwise and network meta-analysis with random effects. We assessed the risk of bias of individual studies with the Cochrane risk of bias tool and confidence of estimates with the Grading of Recommendations Assessment, Development, and Evaluation approach for network meta-analyses. This study is registered with PROSPERO, number CRD42014008976. 133 double-blind randomised controlled trials (81 in children and adolescents, 51 in adults, and one in both) were included. The analysis of efficacy closest to 12 weeks was based on 10 068 children and adolescents and 8131 adults; the analysis of tolerability was based on 11 018 children and adolescents and 5362 adults. The confidence of estimates varied from high or moderate (for some comparisons) to low or very low (for most indirect comparisons). For ADHD core symptoms rated by clinicians in children and adolescents closest to 12 weeks, all included drugs were superior to placebo (eg, SMD -1·02, 95% CI -1·19 to -0·85 for amphetamines, -0·78, -0·93 to -0·62 for methylphenidate, -0·56, -0·66 to -0·45 for atomoxetine). By contrast, for available comparisons based on teachers' ratings, only methylphenidate (SMD -0·82, 95% CI -1·16 to -0·48) and modafinil (-0·76, -1·15 to -0·37) were more efficacious than placebo. In adults (clinicians' ratings), amphetamines (SMD -0·79, 95% CI -0·99 to -0·58), methylphenidate (-0·49, -0·64 to -0·35), bupropion (-0·46, -0·85 to -0·07), and atomoxetine (-0·45, -0·58 to -0·32), but not modafinil (0·16, -0·28 to 0·59), were better than placebo. With respect to tolerability, amphetamines were inferior to placebo in both children and adolescents (odds ratio [OR] 2·30, 95% CI 1·36-3·89) and adults (3·26, 1·54-6·92); guanfacine was inferior to placebo in children and adolescents only (2·64, 1·20-5·81); and atomoxetine (2·33, 1·28-4·25), methylphenidate (2·39, 1·40-4·08), and modafinil (4·01, 1·42-11·33) were less well tolerated than placebo in adults only. In head-to-head comparisons, only differences in efficacy (clinicians' ratings) were found, favouring amphetamines over modafinil, atomoxetine, and methylphenidate in both children and adolescents (SMDs -0·46 to -0·24) and adults (-0·94 to -0·29). We did not find sufficient data for the 26-week and 52-week timepoints. Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs. Stichting Eunethydis (European Network for Hyperkinetic Disorders), and the UK National Institute for Health Research Oxford Health Biomedical Research Centre.

1 March 2013 in American Journal of Psychiatry
Verified
Journal Article
Closed access
ESEdmund Sonuga-Barke
Edmund Sonuga-Barke
DBDaniel Brandeis
Daniel Brandeis
SCSamuele Cortese
Samuele Cortese
DDDavid Daley
David Daley
MFMaite Ferrin
Maite Ferrin
EGEuropean ADHD Guidelines Group
European ADHD Guidelines Group

1 November 2016 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
EMElizabeth Murray
Elizabeth Murray
EHEric B. Hekler
Eric B. Hekler
GAGerhard Andersson
Gerhard Andersson
LCLinda M. Collins
Linda M. Collins
ADAiden Doherty
Aiden Doherty
JWJeremy C. Wyatt
Jeremy C. Wyatt

10 December 2016 in Journal of Child Psychology and Psychiatry
Verified
Journal Article
Closed access
PDF file
CHChris Hollis
Chris Hollis
CFCaroline J. Falconer
Caroline J. Falconer
JMJennifer L. Martin
Jennifer L. Martin
CWCraig Whittington
Craig Whittington
SSSarah Stockton
Sarah Stockton
BDBethan Davies
Bethan Davies

1 October 2017 in The Lancet Psychiatry
Verified
Journal Article
Open access
DFDaniel Freeman
Daniel Freeman
BSBryony Sheaves
Bryony Sheaves
GGGuy M Goodwin
Guy M Goodwin
LYLy-Mee Yu
Ly-Mee Yu
ANAlecia Nickless
Alecia Nickless
CEColin A Espie
Colin A Espie
Sleep difficulties might be a contributory causal factor in the occurrence of mental health problems. If this is true, improving sleep should benefit psychological health. We aimed to determine whether treating insomnia leads to a reduction in paranoia and hallucinations. We did this single-blind, randomised controlled trial (OASIS) at 26 UK universities. University students with insomnia were randomly assigned (1:1) with simple randomisation to receive digital cognitive behavioural therapy (CBT) for insomnia or usual care, and the research team were masked to the treatment. Online assessments took place at weeks 0, 3, 10 (end of therapy), and 22. The primary outcome measures were for insomnia, paranoia, and hallucinatory experiences. We did intention-to-treat analyses. The trial is registered with the ISRCTN registry, number ISRCTN61272251. Between March 5, 2015, and Feb 17, 2016, we randomly assigned 3755 participants to receive digital CBT for insomnia (n=1891) or usual practice (n=1864). Compared with usual practice, the sleep intervention at 10 weeks reduced insomnia (adjusted difference 4·78, 95% CI 4·29 to 5·26, Cohen's d=1·11; p<0·0001), paranoia (-2·22, -2·98 to -1·45, Cohen's d=0·19; p<0·0001), and hallucinations (-1·58, -1·98 to -1·18, Cohen's d=0·24; p<0·0001). Insomnia was a mediator of change in paranoia and hallucinations. No adverse events were reported. To our knowledge, this is the largest randomised controlled trial of a psychological intervention for a mental health problem. It provides strong evidence that insomnia is a causal factor in the occurrence of psychotic experiences and other mental health problems. Whether the results generalise beyond a student population requires testing. The treatment of disrupted sleep might require a higher priority in mental health provision. Wellcome Trust.

7 September 2004 in Journal of Child Psychology and Psychiatry
Verified
Journal Article
Closed access
PDF file
JCJudy CLEGG
Judy CLEGG
CHC. Hollis
C. Hollis
LML. Mawhood
L. Mawhood
MRM. Rutter
M. Rutter